A patient diagnosed with schizophrenia had an exacerbation of hallucinations and delusions related to medication non-adherence and was hospitalized for 10 days. The patient is stabilized and discharge is planned. The patient’s family is concerned that the patient’s symptoms will return after discharge. Acting as an advocate for the patient’s rights, the nurse’s best response is:

Choice A reason: Claiming all mental illnesses can be cured oversimplifies disorders like schizophrenia, which often involve chronic dopamine dysregulation in the prefrontal cortex and limbic system, requiring lifelong management. This approach ignores genetic predispositions and neurobiological complexities, potentially fostering false hope and stigma by implying recovery is universal, disregarding evidence of persistent symptoms in many cases.

Choice B reason: Highlighting creativity and freedom romanticizes mental illnesses, ignoring their debilitating effects. Disorders like bipolar disorder may show creativity in manic phases, but hypomania often impairs judgment and stability. Neuroimaging shows altered amygdala activity in such conditions, causing emotional dysregulation. This portrayal minimizes suffering and misrepresents the neurobiological basis, perpetuating misunderstanding and stigma.

Choice C reason: Correcting misperceptions educates about the neurobiological underpinnings of mental illnesses, such as serotonin imbalances in depression or GABA deficits in anxiety. By addressing myths, nurses promote understanding that these are medical conditions involving brain dysfunction, not personal failings. This fosters empathy, reduces stigma, and aligns with evidence-based approaches to mental health advocacy.

Choice D reason: Attributing most mental illnesses to substance use disorders is inaccurate. While substances can exacerbate symptoms, primary disorders like major depression involve genetic factors and altered neurotransmitter activity, such as reduced serotonin uptake. This oversimplification ignores distinct etiologies, risks misdiagnosis, and perpetuates stigma by blaming patients for their conditions, contrary to scientific evidence.

Choice A reason: Paroxetine, an SSRI, is first-line for GAD, enhancing serotonin in the amygdala and prefrontal cortex, reducing excessive worry. Its efficacy and tolerability, with minimal dependence risk, align with evidence-based guidelines for long-term anxiety management, making it the preferred choice.

Choice B reason: Imipramine, a tricyclic antidepressant, affects serotonin and norepinephrine but has significant anticholinergic side effects, reducing tolerability. It is not first-line for GAD due to slower onset and side effect profile compared to SSRIs, which better target anxiety’s neurobiological basis.

Choice C reason: Hydroxyzine, an antihistamine, reduces anxiety via histamine receptor blockade, causing sedation. It is used as needed, not for chronic GAD management. SSRIs, like paroxetine, offer sustained serotonin modulation, making hydroxyzine a less effective, non-first-line option for long-term treatment.

Choice D reason: Alprazolam, a benzodiazepine, enhances GABA activity, providing rapid anxiety relief but carries high dependence risk. It is not first-line for GAD, as SSRIs offer safer, long-term serotonin-based treatment, making alprazolam unsuitable for chronic management due to addiction potential.